cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.j85wc3
title: Occurrence Download

description: A dataset containing 13 species occurrences available in GBIF matching the query:
{"type":"and","predicates":[{"type":"equals","key":"GADM_LEVEL_0_GID","value":"ARG","matchCase":false},{"type":"equals","key":"GADM_LEVEL_1_GID","value":"ARG.22_1","matchCase":false},{"type":"equals","key":"GADM_LEVEL_2_GID","value":"ARG.22.14_1","matchCase":false},{"type":"equals","key":"CLASS_KEY","value":"212","matchCase":false},{"type":"greaterThanOrEquals","key":"YEAR","value":"2015","matchCase":false},{"type":"not","predicate":{"type":"in","key":"BASIS_OF_RECORD","values":["MATERIAL_CITATION","MATERIAL_SAMPLE","PRESERVED_SPECIMEN"],"matchCase":false}},{"type":"lessThanOrEquals","key":"COORDINATE_UNCERTAINTY_IN_METERS","value":"10000","matchCase":false},{"type":"equals","key":"LICENSE","value":"CC BY 4.0","matchCase":false}]}

 The dataset includes 13 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0058922-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5517/ccdc.csd.cc2q1t6t
title: CCDC 2504186: Experimental Crystal Structure Determination

description: Related Article: E.D. Tselukovskaya, P.V. Dorovatovskii, A.V. Vologzhanina|2025|Acta Crystallogr.,Sect.C:Cryst.Struct.Chem.|81|728|doi:10.1107/S2053229625010423
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2q1t7v
title: CCDC 2504187: Experimental Crystal Structure Determination

description: Related Article: E.D. Tselukovskaya, P.V. Dorovatovskii, A.V. Vologzhanina|2025|Acta Crystallogr.,Sect.C:Cryst.Struct.Chem.|81|728|doi:10.1107/S2053229625010423
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.15468/dl.mwk6jj
title: Occurrence Download

description: A dataset containing 2694 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Eriocephalus africanus",
 "HasCoordinate is true"
 ]
}

 The dataset includes 2694 records from 45 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0058925-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.a4bezr
title: Occurrence Download

description: A dataset containing 1393 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Tagelus plebeius, Siliquaria notata, Solecurtus caribaeus, Solecurtus platensis, Solen caribaeus, Solen gibbus, Solen plebeius, Tagelus gibbus, Tagelus gibbus entrerianus, Tagelus poeyi)",
 "HasCoordinate is true",
 "BasisOfRecord is one of (Observation, Machine Observation, Human Observation, Occurrence evidence)",
 "OccurrenceStatus is Present",
 "Year is greater than or equal to 1950"
 ]
}

 The dataset includes 1393 records from 3 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0058924-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.7284/166797
title: Multiplexed data collected during research cruise AE2501a using a BIOS METOC instrument system onboard the platform RV Atlantic Explorer

description: Original (unprocessed) data collected during a Field_expedition
DOI: 10.7284/166799
title: Multiplexed data collected during research cruise AE2501a using a BIOS METOC instrument system onboard the platform RV Atlantic Explorer

description: Original (unprocessed) data collected during a Field_expedition
DOI: 10.7284/166800
title: Multiplexed data collected during research cruise AE2501a using a BIOS METOC instrument system onboard the platform RV Atlantic Explorer

description: Original (unprocessed) data collected during a Field_expedition
DOI: 10.7284/166801
title: Multiplexed data collected during research cruise AE2501a using a BIOS METOC instrument system onboard the platform RV Atlantic Explorer

description: Original (unprocessed) data collected during a Field_expedition
DOI: 10.7284/166791
title: ADCP (Acoustic Doppler Current Profiler) data collected during research cruise AE2501a using a Hawaii UHDAS instrument system onboard the platform RV Atlantic Explorer

description: Original (unprocessed) data collected during a Field_expedition
DOI: 10.5517/ccdc.csd.cc2pzs3l
title: CCDC 2502230: Experimental Crystal Structure Determination

description: Related Article: feng zhan|2025|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2pzs4m
title: CCDC 2502231: Experimental Crystal Structure Determination

description: Related Article: feng zhan|2025|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2pzs5n
title: CCDC 2502232: Experimental Crystal Structure Determination

description: Related Article: feng zhan|2025|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.17026/ar/4fw2oj
title: PAN-00108050 - coin/coin-related, Nero (54-68), dupondius

description: &lt;p&gt;This find is registered at Portable Antiquities of the Netherlands with number PAN-00108050&lt;/p&gt;
description: Modified: 2025-06-11T07:47:10+02:00
DOI: 10.5517/ccdc.csd.cc2pbn0q
title: CCDC 2482883: Experimental Crystal Structure Determination

description: Related Article: Dr Aswini Kalita|2025|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2pbl6v
title: CCDC 2482827: Experimental Crystal Structure Determination

description: Related Article: Dr Aswini Kalita|2025|CSD Communication|||
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.25505/fiz.icsd.cc2mjdcy
title: CSD 2428830: Experimental Crystal Structure Determination

description: Related Article: Johanna I. Hütner, Andrea Conti, David Kugler, Franziska Sabath, Kim Noelle Dreier, Hans-Georg Stammler, Florian Mittendorfer, Angelika Kühnle, Michael Schmid, Ulrike Diebold, Jan Balajka|2025|Sci. Adv.|11|eaea2378|doi:10.1126/sciadv.aea2378
description: An entry from the Inorganic Crystal Structure Database, the world’s repository for inorganic crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the joint CCDC and FIZ Karlsruhe Access Structures service and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.25934/pr00008427
title: Predictors of exposure, therapeutic and adverse effects of medicines used in the treatment of multiple myeloma

description: Multiple myloma (MM) is a cancer of plasma cells and is on the rise worldwide, particularly in the US, Australia, and Western Europe. Nearly 2% of cancer diagnoses and more than 2% of cancer deaths in the US are due to MM. Since 1990, the global incidence of MM has increased by 126% and US incidence by over 40%, whilst global mortality has increased by 94% [1].
There are many important medicines used in the treatment of multiple myeloma (MM) including ixazomib, daratumumab, and isatuximab. Ixazomib is a proteasome inhibitor which is a drug that inhibit the cellular protein called ‘proteosome’ leading to potein build up and killing of myeloma cells. Daratumumab and isatuximab are monoclonal antibodies are medicines created in the lab and act in a simular fashion to the body’s own antibodies where they help the immune system to recognize and block a specific target. However, response and toxicity to these drugs are highly variable and there are no accurate and reliable tools to date to accurately predict patients who will benefit most. Using the diverse range of data collected from MM clinical trials, including individual’s demographic, clinical, laboratory, disease and genetic characteristics, it is possible to identify predictors and develop clinical tools that enable improved prediction of therapeutic and adverse outcomes from MM medicines. Being able to identify the expected response and adverse effect profile may enable patients and clinicians to make better decisions regarding whether to commence, continue, or change dosing of medicines used in the treatment of MM.
DOI: 10.15468/dl.2gztr8
title: Occurrence Download

description: A dataset containing 9941 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is France",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Pleurozium schreberi"
 ]
}

 The dataset includes 9941 records from 173 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0058926-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/00004746
title: Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study

description: Establishment of safety profile of HuMax-CD38 when given as monotherapy in participants with multiple myeloma relapsed from or refractory to at least 2 different cytoreductive therapies and without further established treatment options.
DOI: 10.25934/00004864
title: An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or Are Double Refractory to a Proteasome Inhibitor and an IMiD

description: The purpose of this study is to evaluate the efficacy and safety of 2 daratumumab treatment regimens in participants with multiple myeloma who have received at least 3 prior lines of therapy (including a proteasome inhibitor [PI] and immunomodulatory drug [IMiD]) or are double refractory to a PI and an IMiD.
DOI: 10.25934/00004870
title: Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma

description: The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple myeloma.
DOI: 10.25934/00004872
title: Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma

description: The purpose of this study is to assess the effects of administration of daratumumab when combined with VELCADE (bortezomib) and dexamethasone compared with bortezomib and dexamethasone alone, for participants with relapsed or refractory multiple myeloma.
DOI: 10.25934/00005200
title: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

description: The purpose of this study is to compare the efficacy of daratumumab in combination with lenalidomide and dexamethasone to that of lenalidomide and dexamethasone in terms of progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not candidates for high dose chemotherapy (treatment of disease, usually cancer, by chemical agents) and autologous stem cell transplant (ASCT).
DOI: 10.25934/00007113
title: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

description: The purpose of this study is to provide continued access to ixazomib and/or lenalidomide to participants who are continuing to have clinical benefit and to continue collecting relevant safety data to monitor safety in participants with Newly Diagnosed Multiple Myeloma (NDMM) who are not eligible for stem cell transplant.
DOI: 10.25934/00007115
title: An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment

description: This is a phase 2, multicenter, open-label study in patients with Newly Diagnosed Multiple Myeloma (NDMM) who have not received prior systemic treatment for multiple myeloma (MM) and who are ineligible for high-dose therapy (HDT)-stem cell transplantation (SCT) due to age (ie, ≥ 65 years) or comorbid disease(s) or with Relapsed and/or Refractory Multiple Myeloma (RRMM).
DOI: 10.25934/00007373
title: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

description: The purpose of this study is to determine whether the addition of oral ixazomib to the background therapy of lenalidomide and dexamethasone improves progression free survival (PFS) in participants with relapsed and/or refractory multiple myeloma (RRMM).
DOI: 10.25934/00007374
title: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

description: The purpose of this study is to determine the effect of ixazomib maintenance therapy on progression free survival (PFS) compared with placebo, in participants with NDMM who have had a major response (complete response [CR], very good partial response [VGPR], or partial response [PR]) to initial therapy and who have not undergone SCT.
DOI: 10.25934/00007380
title: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

description: The China Continuation of Study C16010 was a randomized, double-blind, placebo-controlled evaluation of ixazomib or placebo combined with lenalidomide and dexamethasone (LenDex) in patients with relapsed and/or refractory multiple myeloma (RRMM) in China. The primary purpose of the China continuation was to allow evaluation of efficacy, to assess any emerging safety signals, to provide characterization of the PK properties, and to provide sufficient evidence to support registration of Ixazomib in China. After the primary analysis of PFS occurred in July 2015, the study continued in a double-blind, placebo-controlled manner to obtain mature overall survival (OS) information. A subset of 20 patients were included in the PK portion of the study.
DOI: 10.25934/pr00007736
title: A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

description: Primary Objective: To demonstrate the benefit of isatuximab in combination with pomalidomide and low-dose dexamethasone in the prolongation of Progression Free Survival (PFS) as compared to pomalidomide and low-dose dexamethasone in participants with refractory or relapsed and refractory multiple myeloma (MM). Secondary Objectives:   -  To evaluate the Overall Response Rate (ORR) as per International Myeloma Working Group (IMWG) criteria in each arm.   -  To compare the Overall Survival (OS) between the two arms.   -  To evaluate the Time To Progression (TTP) in each arm.   -  To evaluate the PFS in high risk cytogenetic population in each arm.   -  To evaluate the Duration of Response (DOR) in each arm.   -  To evaluate the safety in both treatment arms.   -  To determine the Pharmacokinetic profile of isatuximab in combination with pomalidomide.   -  To evaluate the immunogenicity of isatuximab.   -  To assess disease-specific and generic health-related quality of life (HRQL), disease and treatment-related symptoms, health state utility, and health status.
DOI: 10.15468/dl.cy3dfe
title: Occurrence Download

description: A dataset containing 5 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Monoxia apicalis Blake, 1939"
 ]
}

 The dataset includes 5 records from 4 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0130105-230224095556074/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.xbmh54
title: Occurrence Download

description: A dataset containing 632051 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((-2.51862 36.65424,-1.409 36.65424,-1.409 37.59152,-2.51862 37.59152,-2.51862 36.65424))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false"
 ]
}

 The dataset includes 632051 records from 293 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0281973-210914110416597/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.wf4kmb
title: Occurrence Download

description: A dataset containing 201798 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is one of (Ireland, United Kingdom of Great Britain and Northern Ireland, Portugal, Spain, France, Germany, Belgium, Netherlands, Italy, Greece, Denmark, Norway, Sweden, Finland, Svalbard and Jan Mayen, Estonia, Latvia, Lithuania, Türkiye, Russian Federation, Belarus, Ukraine, Moldova, Republic of, Switzerland, Austria, Poland, Czechia, Hungary, Slovakia, Romania, Bulgaria, Kazakhstan, Armenia, North Macedonia, Albania, Serbia, Montenegro, Kosovo, Bosnia and Herzegovina, Croatia, Slovenia, Cyprus)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Cichorium intybus L."
 ]
}

 The dataset includes 201798 records from 1489 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0015627-240425142415019/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.9v27zk
title: Occurrence Download

description: A dataset containing 1 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Gobius gymnocephalus Bleeker, 1853",
 "Country is India"
 ]
}

 The dataset includes 1 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0016951-160910150852091/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.wjc2sa
title: Occurrence Download

description: A dataset containing 685 species occurrences available in GBIF matching the query:
{
 "and" : [
 {
 "and" : [
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is one of (Fossil, Living Specimen)"
 ]
 }
 }
 ]
 },
 "TaxonKey is Brachymeles taylori Brown, 1956"
 ]
}

 The dataset includes 685 records from 4 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0083198-240229165702484/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.earmw4
title: Occurrence Download

description: A dataset containing 1582 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is China",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is Actinidia chinensis Planch."
 ]
}

 The dataset includes 1582 records from 18 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0023058-231120084113126/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.nzp6nf
title: Occurrence Download

description: A dataset containing 1617 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is one of (Human Observation, Material sample, Specimen)",
 "Country is one of (South Africa, Eswatini, Tanzania, United Republic of, Lesotho, Kenya, Malawi, Zimbabwe, Mozambique)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Dierama K.Koch"
 ]
}

 The dataset includes 1617 records from 28 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0083179-240229165702484/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.w6pqac
title: Occurrence Download

description: A dataset containing 15257 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "DatasetKey is IndOBIS, Indian Ocean Node of OBIS"
 ]
}

 The dataset includes 15257 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0016952-160910150852091/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.